Accredited Continuing Education

Accreditation Statement   

The Society for Cardiovascular Angiography and Interventions is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation  

The Society for Cardiovascular Angiography and Interventions designates this live activity for a maximum of 12.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

ABIM MOC  

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

Learning Objectives  

Upon completion of this activity, participants will be able to:  

  • Discuss the diagnosis of cardiogenic shock, incorporating the SCAI clinical expert consensus statement on the classification of cardiogenic shock.  
  • Analyze the latest shock trials and shock initiatives, including system-based protocols and for multidisciplinary shock teams, shock centers, and care networks.  
  • Incorporating the SCAI Consensus Document on Mechanical Support Devices, explain recommendations for both cardiac support device utilization and for cardiac intensive care unit management.  
  • Compare cardiogenic shock treatments and protocols around the globe, assess disparities in shock care, and evaluate cardiogenic shock cases.  

Acknowledgment of Commercial Support  

SCAI has not received commercial support for this activity. No in-kind commercial support was received.   

Disclosures  

Individuals in control of content disclosed the following relevant financial relationships with commercial interests.  

Faculty  

Faculty disclosures are available in the Faculty Index in the app.  

Program Committee   

William O'Neill, MD, FSCAI, Program Chair: Consultant with Abiomed, Abbott, Boston Scientific, and Medtronic. Alexander Truesdell, MD, FSCAI, Program Co-Chair: Consultant and speaker with Abiomed Inc. Perwai Meraj, MD, FSCAI, Program Co-Chair: Advisory board member with Abiomed and Medtronic.  

CME Oversight Committee  

Patricia J. Best, MD, FSCAI, and William Penny, MD, FSCAI have no relevant financial relationships with ineligible companies to disclose.  

Staff 

Robert C. Bartel, MSc, FACEHP, and Rachel Pham, CMP have no relevant financial relationships with commercial interests to disclose.  

SCAI’s Independent Content  

As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities. All participating faculty, course directors, planning committee members, and staff are required to disclose to SCAI any relevant financial relationships. SCAI identifies relevant conflicts of interest and mitigates them before the activity begins.  

Planning Process  

SCAI activities are developed by the SCAI SHOCK Planning Committee prior to and independent of commercial support. Members of the Education Committee reviewed and approved this activity, and those with relevant conflicts of interest recused themselves. Members of SCAI’s Continuing Medical Education Oversight Committee, clinicians in the field of cardiac catheterization and angiography, reviewed all educational materials and verified that the materials are fair, accurate, and free of commercial bias.   

Content Validation Statement  

SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations. All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection, and analysis.  

SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.